JPWO2023095510A5 - - Google Patents
Info
- Publication number
- JPWO2023095510A5 JPWO2023095510A5 JP2024531227A JP2024531227A JPWO2023095510A5 JP WO2023095510 A5 JPWO2023095510 A5 JP WO2023095510A5 JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024531227 A JP2024531227 A JP 2024531227A JP WO2023095510 A5 JPWO2023095510 A5 JP WO2023095510A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2021/043459 | 2021-11-26 | ||
| PCT/JP2021/043459 WO2023095305A1 (en) | 2021-11-26 | 2021-11-26 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| PCT/JP2022/039605 WO2023095510A1 (en) | 2021-11-26 | 2022-10-25 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024543147A JP2024543147A (ja) | 2024-11-19 |
| JPWO2023095510A5 true JPWO2023095510A5 (https=) | 2025-10-30 |
| JP2024543147A5 JP2024543147A5 (https=) | 2025-10-30 |
Family
ID=86539186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531227A Pending JP2024543147A (ja) | 2021-11-26 | 2022-10-25 | 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250034265A1 (https=) |
| JP (1) | JP2024543147A (https=) |
| KR (1) | KR20240107372A (https=) |
| CN (1) | CN118591389A (https=) |
| AU (1) | AU2022398430A1 (https=) |
| CA (1) | CA3238940A1 (https=) |
| IL (1) | IL313058A (https=) |
| MX (1) | MX2024006393A (https=) |
| TW (1) | TW202330030A (https=) |
| WO (3) | WO2023095305A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| IL287220B2 (en) | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20120039840A1 (en) | 2008-12-02 | 2012-02-16 | Hunter Christopher A | Use of IL-27-P28 to antagonize IL-6 mediated signaling |
| JP6130983B2 (ja) * | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
-
2021
- 2021-11-26 WO PCT/JP2021/043459 patent/WO2023095305A1/en not_active Ceased
-
2022
- 2022-10-25 CA CA3238940A patent/CA3238940A1/en active Pending
- 2022-10-25 AU AU2022398430A patent/AU2022398430A1/en active Pending
- 2022-10-25 JP JP2024531227A patent/JP2024543147A/ja active Pending
- 2022-10-25 KR KR1020247021082A patent/KR20240107372A/ko active Pending
- 2022-10-25 MX MX2024006393A patent/MX2024006393A/es unknown
- 2022-10-25 WO PCT/JP2022/039605 patent/WO2023095510A1/en not_active Ceased
- 2022-10-25 TW TW111140385A patent/TW202330030A/zh unknown
- 2022-11-25 IL IL313058A patent/IL313058A/en unknown
- 2022-11-25 WO PCT/JP2022/043437 patent/WO2023095852A1/en not_active Ceased
- 2022-11-25 CN CN202280089989.0A patent/CN118591389A/zh active Pending
- 2022-11-25 US US18/712,917 patent/US20250034265A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021183359A5 (https=) | ||
| van der Meché et al. | The current place of high‐dose immunoglobulins in the treatment of neuromuscular disorders | |
| JPWO2023095510A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| RU2011117293A (ru) | Композиция для лечения заболевания | |
| Tumani | Corticosteroids and plasma exchange in multiple sclerosis | |
| JPWO2021224499A5 (https=) | ||
| Graves et al. | Immunotherapies in neurologic disorders | |
| Tenembaum | Therapy of multiple sclerosis in children and adolescents | |
| EP4193995A1 (en) | Use of btk inhibitors in the treatment of diseases | |
| CN119894516A (zh) | 用于治疗晚期实体瘤的组合物和方法 | |
| Carver et al. | Treatment of pediatric pemphigus foliaceus | |
| JPWO2022198192A5 (https=) | ||
| JPWO2020186132A5 (https=) | ||
| AU2019237774B2 (en) | Anti-VEGFR-2 antibody | |
| JPWO2021050645A5 (https=) | ||
| JPWO2022098648A5 (https=) | ||
| JPWO2023140269A5 (https=) | ||
| Khim | Myasthenia gravis treatment | |
| EP4316518A1 (en) | Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody | |
| CN118767126A (zh) | 抗cd47抗体和阿扎胞苷联合治疗血液肿瘤 | |
| US20260115282A1 (en) | Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody | |
| JPWO2021090272A5 (https=) | ||
| Askins et al. | Evolving role of the Interleukin-5 antagonist mepolizumab for hypereosinophilic syndrome: pathogenesis and advances in therapy-A narrative review | |
| JPWO2023180353A5 (https=) |